Details

Autor(en) / Beteiligte

• Rageth, Christoph J.
• O’Flynn, Elizabeth AM
• Comstock, Christopher
• Kurtz, Claudia
• Kubik, Rahel
• Madjar, Helmut
• Lepori, Domenico
• Kampmann, Gert
• Mundinger, Alexander
• Baege, Astrid
• Decker, Thomas
• Hosch, Stefanie
• Tausch, Christoph
• Delaloye, Jean-François
• Morris, Elisabeth
• Varga, Zsuzsanna

Titel

First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

Ist Teil von

• Breast Cancer Research and Treatment, 2016-09, Vol.159 (2), p.203-213

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2016

Quelle

SpringerLink

Beschreibungen/Notizen

• The purpose of this study is to obtain a consensus for the therapy of B3 lesions. The first International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) including atypical ductal hyperplasia (ADH), flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL), benign phyllodes tumors (PT), and radial scars (RS) took place in January 2016 in Zurich, Switzerland organized by the International Breast Ultrasound School and the Swiss Minimally Invasive Breast Biopsy group—a subgroup of the Swiss Society of Senology. Consensus recommendations for the management and follow-up surveillance of these B3 lesions were developed and areas of research priorities were identified. The consensus recommendation for FEA, LN, PL, and RS diagnosed on core needle biopsy or vacuum-assisted biopsy (VAB) is to therapeutically excise the lesion seen on imaging by VAB and no longer by open surgery, with follow-up surveillance imaging for 5 years. The consensus recommendation for ADH and PT is, with some exceptions, therapeutic first-line open surgical excision. Minimally invasive management of selected B3 lesions with therapeutic VAB is acceptable as an alternative to first-line surgical excision.